Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Doubling Multiple Sclerosis Sales Force For Antegren Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will have almost 200 MS sales reps by the time Antegren is expected to launch in early 2005. Partner Elan also will contribute specialty reps for the hospital outpatient setting. Biogen Idec's pre-launch efforts are focusing on reimbursement and neurologists' capacities for I.V. administration.
Advertisement

Related Content

Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
Elan Dismisses Merger Speculation
Elan Dismisses Merger Speculation
Avonex Manufacturing Update: New Liquid Fill-Finish Process Validated
Avonex Manufacturing Update: New Liquid Fill-Finish Process Validated
Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End
Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End

Topics

Advertisement
UsernamePublicRestriction

Register

PS060165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel